Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure

AIDS Research and Therapy

Alain Lafeuillade¹  Vicente Soriano⁵  Marie Suzan-Monti³  Mario Stevenson²  Jacques Izopet⁶  Hans-Jürgen Stellbrink⁴ 

[1] Department of Infectious Diseases, General Hospital, Toulon, France

[2] Miller MedicalSchool, University of Miami, Miami, FL, USA

[3] ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille, France

[4] Infektions Medizinisches Centrum Hamburg Study Center, Hamburg, Germany

[5] Department of Infectious Diseases Hospital Carlos III, Madrid, Spain

[6] Laboratoire de Virologie, Institut Fédératif de Biologie, Hôpital Purpan, Toulouse, France

关键词: New anti-HCV drugs;    Access to care;    HCV coinfection;    Antiretroviral therapy;    HIV reservoirs;    HIV cure;    HIV pandemic;   

Others  :  789647
DOI  :  10.1186/1742-6405-9-23

 received in 2012-07-06, accepted in 2012-07-19,  发布年份 2012

【 摘 要 】

The 2012 International Symposium on HIV and Emerging Infectious Diseases (ISHEID) provided a forum for investigators to hear the latest research developments in the clinical management of HIV and HCV infections as well as HIV-1 reservoirs and cure research. Combined anti-retroviral therapy (c-ART) has had a profound impact on the disease prognosis of individuals living with HIV-1 infection. However, although these anti-retroviral regimens are able to reduce plasma viremia to below the limits of detection for sustained periods of time, there is a rapid recrudescence in plasma viremia if treatment is interrupted. Therefore, despite this potent anti-retroviral suppression, HIV-1 is able to persist within the infected individual. The main 2012 ISHEID theme was, hence “searching for an HIV cure”. In this report we not only give details on this main topic of the 2012 ISHEID but also summarize what has been discussed in the areas of HIV epidemiology, access to care, antiretroviral therapy management and recent progress in the therapy of HCV infection in patients with HIV.

【 授权许可】

   
2012 Lafeuillade et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Ekström A: Update on HIV pandemic. Retrovirology 2012, 9(Suppl 1):I4. BioMed Central Full Text
• [2]Shamas S: HIV epidemic in Bulgaria. Retrovirology 2012, 9(Suppl 1):P89. BioMed Central Full Text
• [3]WHO UNAIDS UNICEF: Global HIV/AIDS response - Epidemic update and health sector progress towards universal access. 2011. http://wwwunaidsorg/en/media/unaids/contentassets/documents/unaidspublication/2011/20111130_UA_Report_enpdf webcite
• [4]Souteyrand Y: Universal access to anti-HIV therapy. Retrovirology 2012, 9(Suppl 1):I13. BioMed Central Full Text
• [5]Rosen S, Fox MP: Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011, 8(7):e1001056. Epub 2011 Jul 19
• [6]Juárez-Figueroa L, González-Rodríguez A, Rodríguez-Nolasco E: Integral HIV-STI diagnosis at the first VCT visit as strategy to prevent late ART initiation in the HIV-AIDS program of Mexico City (HIVPMC). Retrovirology 2012, 9(Suppl 1):P73.
• [7]WHO UNAIDS: The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support. 2011. http://wwwunaidsorg/en/media/unaids/contentassets/documents/unaidspublication/2011/20110824_JC2208_outlook_treatment20_enpdf webcite
• [8]Fahim S, Shastri S, Washington R: Scaling up HIV treatment-Karnataka, India experience. Retrovirology 2012, 9(Suppl 1):P71.
• [9]Fahim S, Shastri S, Rewari B: Decentralizing treatment services with link ART centres- experience from Karnataka, South India. Retrovirology 2012, 9(Suppl 1):P82. BioMed Central Full Text
• [10]Grigoryan S, Mkrtchyan A: Access to HIV treatment and care in Armenia. Retrovirology 2012, 9(Suppl 1):P75.
• [11]Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, et al.: Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS One 2012, 7:e30216.
• [12]Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, et al.: Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS 2012, 26:45-56.
• [13]Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, et al.: Routine HIV screening in France: clinical impact and cost-effectiveness. PLoS One 2010, 5:e13132.
• [14]Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al.: HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009, 48:806-815.
• [15]Cohen J: Breakthrough of the year. HIV treatment as prevention. Science 2011, 334:1628.
• [16]Lange JM: "Test and treat": is it enough? Clin Infect Dis 2011, 52:801-802.
• [17]Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ: The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800.
• [18]Wainberg MA: Pre-exposure prophylaxis against HIV: pros and cons. Retrovirology 2012, 9(Suppl 1):I6. BioMed Central Full Text
• [19]Abdool-Karim SS, Abdool-Karim Q: Antiretroviral prophylaxis: a defining moment in HIV control. Lancet 2011, 378:e23-e25.
• [20]ANRS: ANRS IPERGAY - Intervention Préventive de l'Exposition aux Risques avec et pour les Gays. 2012. http://wwwanrsfr/content/download/4097/21774/file/ANRS%20IPERGAYpdf webcite
• [21]Silvestri G: Animal models of functional HIV cure. Retrovirology 2012, 9(suppl 1):I9. BioMed Central Full Text
• [22]Van Lint C: Molecular control of HIV-1 postintegration latency: implications for therapeutic strategies. Retrovirology 2012, 9(suppl 1):I10. BioMed Central Full Text
• [23]Chun TW: Towards a cure for HIV: a long road ahead. Retrovirology 2012, 9(suppl 1):I12. BioMed Central Full Text
• [24]Geleziunas R, Stepan G, Wei G, et al.: Search for small molecule activators of latent HIV. Retrovirology 2012, 9(Suppl 1):O2. BioMed Central Full Text
• [25]Shan L, Deng K, Shroff NS, et al.: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36(3):491-501. Epub 2012 Mar 8
• [26]Mousseau G, Mark Clementz MA, Bakeman WN, et al.: Potent suppression of HIV viral replication by a novel inhibitor of Tat. Retrovirology 2012, 9(Suppl 1):O11. BioMed Central Full Text
• [27]Rafati H, Moshkin Y, Mahmoudi T, et al.: New transcription regulatory mechanisms of latent HIV LTR. Retrovirology 2012, 9(Suppl 1):O3. BioMed Central Full Text
• [28]Moreno S: Anti-latency agents to purge HIV reservoirs. Retrovirology 2012, 9(Suppl 1):I16. BioMed Central Full Text
• [29]Stevenson M: A roadmap to a cure. Retrovirology 2012, 9(Suppl 1):I11. BioMed Central Full Text
• [30]Gulick R: New Antiretrovirals. Retrovirology 2012, 9(Suppl 1):I7. BioMed Central Full Text
• [31]Pawlotsky JM: New antiviral agents for hepatitis C. F1000. Biol Rep 2012, 4:5. Epub 2012 Mar 1
• [32]Back D: New drug interactions in HIV and HCV. Retrovirology 2012, 9(Suppl 1):I8. BioMed Central Full Text
• [33]Vella S, Schwartländer B, Sow SP, Eholie SP, Murphy RL: The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 2012, 26(10):1231-1241.
• [34]Rockstroh J: Managing antiretrovirals in co-infected patients in 2012. Retrovirology 2012, 9(Suppl 1):I1. BioMed Central Full Text
• [35]Arab-Alameddine M, Décosterd LA, Buclin T, Telenti A, Csajka C: Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opin Drug MetabToxicol 2011. [Epub ahead of print]
• [36]Goujard C, Primary HIV: infection: the French experience. Retrovirology 2012, 9(Suppl 1):I14. BioMed Central Full Text
• [37]Routy JP: Treating since the beginning? Retrovirology 2012, 9(Suppl 1):I15. BioMed Central Full Text
• [38]Strain MC, Little SJ, Daar ES, et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191(9):1410-1418. Epub 2005 Mar 29
• [39]Pol S: What happens after hepatitis C eradication? Retrovirology 2012, 9(Suppl 1):I19. BioMed Central Full Text
• [40]Lin H, Lee S, Yu M, et al.: Epidemiology of hepatitis delta virus infection in HIV-infected individuals in Taiwan. Retrovirology 2012, 9(Suppl 1):P49. BioMed Central Full Text
• [41]Soriano V, Barreiro P, Vispo E, Labarga P, Soriano V: Management and Treatment of Chronic Hepatitis C in HIV Patients. Semin Liver Dis 2012, 32(2):138-146. Epub 2012 Jul 3
• [42]Soriano V, Zeuzem S, Zoulim F: Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J AntimicrobChemother 2008, 62:1-4.
• [43]Halfon P: HCV resistance. Retrovirology 2012, 9(Suppl 1):I18. BioMed Central Full Text
• [44]Cevik M, Singh G, Dickinson L, et al.: Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals. Retrovirology 2012, 9(Suppl 1):O7. BioMed Central Full Text
• [45]Andre P: Hepatitis C as a metabolic disease. Retrovirology 2012, 9(Suppl 1):I17. BioMed Central Full Text